CHICAGO — Pembrolizumab plus axitinib continued to confer a survival benefit vs. sunitinib at 5-year follow-up as first-line therapy for patients with advanced clear cell renal cell carcinoma, according to study results. The long-term data, presented at ASCO Annual Meeting, showed improved outcomes with the combination even though more patients in the sunitinib group had subsequent